SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-224024
Filing Date
2019-08-19
Accepted
2019-08-19 07:09:39
Documents
14
Period of Report
2019-08-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d782062d8k.htm   iXBRL 8-K 29177
2 EX-99.1 d782062dex991.htm EX-99.1 9947
6 GRAPHIC g782062g0819103943603.jpg GRAPHIC 4297
  Complete submission text file 0001193125-19-224024.txt   172827

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20190816.xsd EX-101.SCH 3105
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20190816_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20190816_pre.xml EX-101.PRE 11431
7 EXTRACTED XBRL INSTANCE DOCUMENT d782062d8k_htm.xml XML 3362
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 191034905
SIC: 2834 Pharmaceutical Preparations